Insilico Medicine
PulseAugur coverage of Insilico Medicine — every cluster mentioning Insilico Medicine across labs, papers, and developer communities, ranked by signal.
- 2026-06-22 partnership Insilico Medicine and SK Biopharmaceuticals Co. have formed a research and development collaboration valued at up to $2.5 billion to discover AI-driven drug candidates for CNS neuroinflammatory diseases. source
- 2026-06-22 partnership Insilico Medicine and SK Biopharmaceuticals have partnered on an AI-driven drug discovery initiative with a potential value exceeding $2.5 billion. source
- 2026-06-02 funding Eli Lilly acquired AI-designed drugs from Insilico Medicine for $2.75 billion. source
- 2026-06-02 funding Eli Lilly acquired drug candidates from Insilico Medicine for $2.75 billion. source
- 2026-06-02 funding Eli Lilly acquired drug candidates from Insilico Medicine for $2.75 billion. source
- 2026-06-02 funding Eli Lilly and Company acquired drug candidates from Insilico Medicine for $2.75 billion. source
- 2026-05-27 partnership Insilico Medicine and Human Longevity have partnered to build AI foundation models for disease prediction. source
- 2026-05-27 partnership Insilico Medicine and Human Longevity formed a partnership to develop AI models for disease prediction. source
- 2026-05-18 funding Eli Lilly acquired drug candidates from Insilico Medicine for $2.75 billion. source
- 2026-05-18 funding Eli Lilly acquired drug candidates from Insilico Medicine for $2.75 billion. source
- 2026-05-18 funding Eli Lilly acquired drug candidates from Insilico Medicine for $2.75 billion. source
- 2026-04-30 funding Eli Lilly invested $2.75 billion in Insilico Medicine for AI-designed drugs. source
3 day(s) with sentiment data
-
Insilico Medicine and SK Biopharmaceuticals ink $2.5B AI drug discovery deal
Insilico Medicine and SK Biopharmaceuticals have entered into a significant research collaboration valued at over $2.5 billion. The partnership will leverage Insilico's AI-driven Pharma.AI platform to discover novel dru…
-
China's biotech industry expands globally despite US pressure
Chinese biotech firms are pushing for global expansion despite facing significant pressure and regulatory hurdles from the United States. These companies are increasingly turning to overseas licensing deals to access in…
-
Eli Lilly pays $2.75B for AI-designed drugs from Insilico Medicine
Eli Lilly and Company has acquired drug candidates designed by Insilico Medicine for $2.75 billion. This significant investment highlights the growing role of artificial intelligence in pharmaceutical research and devel…
-
Insilico Medicine addresses Abu Dhabi secondary listing rumors
Insilico Medicine has addressed recent media reports suggesting a potential secondary listing in Abu Dhabi. While the company stated it continuously evaluates capital operations, including secondary listings, it current…
-
Insilico and Human Longevity partner on AI disease prediction models
Insilico Medicine and Human Longevity have formed a partnership to develop AI foundation models aimed at predicting diseases decades in advance. This collaboration combines Insilico's AI algorithms with Human Longevity'…
-
Insilico Medicine develops AI for human longevity, sparking ethical debate
Insilico Medicine is developing an AI model focused on human longevity, aiming to predict and potentially influence lifespan. This initiative raises significant ethical questions regarding the use of algorithms in such …
-
Eli Lilly invests $2.75B in AI-designed drugs from Insilico Medicine
Eli Lilly has acquired drug candidates designed by Insilico Medicine for $2.75 billion, highlighting AI's growing role in pharmaceutical discovery. This significant investment underscores a broader trend, with the pharm…
-
AI models like MAML accelerate drug discovery, targeting cancer
AI is revolutionizing drug discovery, with new multimodal models like MAML capable of understanding complex biological interactions. These advanced AIs can identify novel treatments for diseases such as cancer and repur…
-
METiS TechBio debuts on Hong Kong stock market with AI-driven drug delivery tech
METiS TechBio, a Hong Kong-listed biotech firm, has successfully debuted on the stock market, with its shares surging significantly on its first day of trading. The company utilizes artificial intelligence to design and…
-
Eli Lilly bets $2.75B on AI drug discovery firm Insilico Medicine
Eli Lilly has invested $2.75 billion in Insilico Medicine, a Hong Kong-based company, for AI-designed drugs. This significant deal highlights the growing trend of major pharmaceutical companies leveraging artificial int…
-
AI models show potential to match or exceed doctor capabilities for basic health questions
Experts suggest consumers should increase their use of AI for health-related inquiries, as certain AI models demonstrate capabilities comparable to or exceeding those of doctors for basic health questions. While AI is a…